Alvocidib free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596713

CAS#: 146426-40-6 (free base)

Description: Alvocidib is a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity. Check for active clinical trials or closed clinical trials using this agent.


Chemical Structure

img
Alvocidib free base
CAS# 146426-40-6 (free base)

Theoretical Analysis

MedKoo Cat#: 596713
Name: Alvocidib free base
CAS#: 146426-40-6 (free base)
Chemical Formula: C21H20ClNO5
Exact Mass: 401.103
Molecular Weight: 401.84
Elemental Analysis: C, 62.77; H, 5.02; Cl, 8.82; N, 3.49; O, 19.91

Price and Availability

Size Price Availability Quantity
50.0mg USD 450.0 2 Weeks
100.0mg USD 750.0 2 Weeks
200.0mg USD 1250.0 2 Weeks
500.0mg USD 2150.0 2 Weeks
1.0g USD 3250.0 2 Weeks
2.0g USD 4950.0 2 Weeks
5.0g USD 7650.0 2 Weeks
Bulk inquiry

Related CAS #: 131740-09-5 (HCl)   146426-40-6 (free base)    

Synonym: L 86-8275; L-868275; L 868275; L868275; HMR 1274; HMR-1274; HMR1274; Flavoperidol; Alvocidib;

IUPAC/Chemical Name: 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3R,4S)-3-hydroxy-1-methylpiperidin-4-yl)-4H-chromen-4-one

InChi Key: BIIVYFLTOXDAOV-PXAZEXFGSA-N

InChi Code: InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m1/s1

SMILES Code: O=C1C=C(C2=CC=CC=C2Cl)OC3=C([C@H]4[C@@H](O)CN(C)CC4)C(O)=CC(O)=C13

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 401.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zocchi L, Wu SC, Wu J, Hayama KL, Benavente CA. The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells. Oncotarget. 2018 May 4;9(34):23505-23518. doi: 10.18632/oncotarget.25239. eCollection 2018 May 4. PubMed PMID: 29805751; PubMed Central PMCID: PMC5955096.

2: Bogenberger J, Whatcott C, Hansen N, Delman D, Shi CX, Kim W, Haws H, Soh K, Lee YS, Peterson P, Siddiqui-Jain A, Weitman S, Stewart K, Bearss D, Mesa R, Warner S, Tibes R. Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget. 2017 Nov 3;8(63):107206-107222. doi: 10.18632/oncotarget.22284. eCollection 2017 Dec 5. PubMed PMID: 29291023; PubMed Central PMCID: PMC5739808.

3: Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, Grant S. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer. 2018 Feb 6;118(3):388-397. doi: 10.1038/bjc.2017.432. Epub 2017 Dec 14. PubMed PMID: 29241222; PubMed Central PMCID: PMC5808038.

4: Pawlak A, DE Miguel D, Kutkowska J, Obmińska-Mrukowicz B, Rapak A, Martinez-Lostao L. Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis. Anticancer Res. 2017 Dec;37(12):6655-6665. PubMed PMID: 29187441.

5: Lashgari A, Millau JF, Jacques PÉ, Gaudreau L. Global inhibition of transcription causes an increase in histone H2A.Z incorporation within gene bodies. Nucleic Acids Res. 2017 Dec 15;45(22):12715-12722. doi: 10.1093/nar/gkx879. PubMed PMID: 29036442; PubMed Central PMCID: PMC5727466.

6: Robak P, Robak T. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 Nov;26(11):1249-1265. doi: 10.1080/13543784.2017.1384814. Epub 2017 Oct 3. Review. PubMed PMID: 28942659.

7: Zhang Y, Zhou L, Leng Y, Dai Y, Orlowski RZ, Grant S. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget. 2017 Aug 1;8(35):59476-59491. doi: 10.18632/oncotarget.19761. eCollection 2017 Aug 29. PubMed PMID: 28938651; PubMed Central PMCID: PMC5601747.

8: Martín Del Campo JS, Eckshtain-Levi M, Sobrado P. Identification of eukaryotic UDP-galactopyranose mutase inhibitors using the ThermoFAD assay. Biochem Biophys Res Commun. 2017 Nov 4;493(1):58-63. doi: 10.1016/j.bbrc.2017.09.074. Epub 2017 Sep 15. PubMed PMID: 28919416.

9: Prasad V, Suomalainen M, Hemmi S, Greber UF. Cell Cycle-Dependent Kinase Cdk9 Is a Postexposure Drug Target against Human Adenoviruses. ACS Infect Dis. 2017 Jun 9;3(6):398-405. doi: 10.1021/acsinfecdis.7b00009. Epub 2017 Apr 27. PubMed PMID: 28434229.

10: Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25;8(17):28696-28710. doi: 10.18632/oncotarget.15645. PubMed PMID: 28404924; PubMed Central PMCID: PMC5438684.

11: LaCerte C, Ivaturi V, Gobburu J, Greer JM, Doyle LA, Wright JJ, Karp JE, Rudek MA. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. Clin Cancer Res. 2017 Jul 15;23(14):3592-3600. doi: 10.1158/1078-0432.CCR-16-2629. Epub 2017 Feb 7. PubMed PMID: 28174232; PubMed Central PMCID: PMC5511568.

12: Hoodless LJ, Lucas CD, Duffin R, Denvir MA, Haslett C, Tucker CS, Rossi AG. Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo. Sci Rep. 2016 Nov 11;5:36980. doi: 10.1038/srep36980. PubMed PMID: 27833165; PubMed Central PMCID: PMC5105078.

13: Li C, Zhang J, Zhu PQ, Ma CH, Yuan LH, Lu J, Luo ZZ, Xu GH. Intrathecal Administration of Flavopiridol Promotes Regeneration in Experimental Model of Spinal Cord Injury. Turk Neurosurg. 2016;26(6):922-929. doi: 10.5137/1019-5149.JTN.13745-15.2. PubMed PMID: 27476919.

14: Cimini A, d'Angelo M, Benedetti E, D'Angelo B, Laurenti G, Antonosante A, Cristiano L, Di Mambro A, Barbarino M, Castelli V, Cinque B, Cifone MG, Ippoliti R, Pentimalli F, Giordano A. Flavopiridol: An Old Drug With New Perspectives? Implication for Development of New Drugs. J Cell Physiol. 2017 Feb;232(2):312-322. doi: 10.1002/jcp.25421. Epub 2016 Jun 2. PubMed PMID: 27171480.

15: Bozok Cetintas V, Acikgoz E, Yigitturk G, Demir K, Oktem G, Tezcanli Kaymaz B, Oltulu F, Aktug H. Effects of flavopiridol on critical regulation pathways of CD133high/CD44high lung cancer stem cells. Medicine (Baltimore). 2016 Oct;95(43):e5150. PubMed PMID: 27787370; PubMed Central PMCID: PMC5089099.

16: Aktug H, Acikgoz E, Uysal A, Oltulu F, Oktem G, Yigitturk G, Demir K, Yavasoglu A, Bozok Cetintas V. Comparison of cell cycle components, apoptosis and cytoskeleton-related molecules and therapeutic effects of flavopiridol and geldanamycin on the mouse fibroblast, lung cancer and embryonic stem cells. Tumour Biol. 2016 Sep;37(9):12423-12440. Epub 2016 Jun 21. PubMed PMID: 27324070.

17: Srikumar T, Padmanabhan J. Potential Use of Flavopiridol in Treatment of Chronic Diseases. Adv Exp Med Biol. 2016;929:209-228. Review. PubMed PMID: 27771926.

18: Matrone G, Mullins JJ, Tucker CS, Denvir MA. Effects of Cyclin Dependent Kinase 9 inhibition on zebrafish larvae. Cell Cycle. 2016 Nov 16;15(22):3060-3069. Epub 2016 Oct 7. PubMed PMID: 27715402; PubMed Central PMCID: PMC5134698.

19: Mi G, Gao Y, Liu S, Ye E, Li Y, Jin X, Yang H, Yang Z. Cyclin-dependent kinase inhibitor flavopiridol promotes remyelination in a cuprizone induced demyelination model. Cell Cycle. 2016 Oct 17;15(20):2780-91. doi: 10.1080/15384101.2016.1220458. Epub 2016 Aug 11. PubMed PMID: 27580304; PubMed Central PMCID: PMC5053583.

20: Oqani RK, Lin T, Lee JE, Kim SY, Sa SJ, Woo JS, Jin DI. Inhibition of P-TEFb disrupts global transcription, oocyte maturation, and embryo development in the mouse. Genesis. 2016 Sep;54(9):470-82. doi: 10.1002/dvg.22961. Epub 2016 Aug 18. PubMed PMID: 27488304.